Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study of the Effect of Adalimumab on Physical Function and Musculoskeletal Disease in Mucopolysaccharidosis Types I, II, and VI

NCT03153319 is registered in ClinicalTrials.gov with Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center as lead sponsor.

NCT NCT03153319
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03153319 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study of the Effect of Adalimumab on Physical Function and Musculoskeletal Disease in Mucopolysaccharidosis Types I, II, and VI
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
June 5, 2017
Completion date
February 28, 2027
Enrollment
14 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mucopolysaccharidosis i, mucopolysaccharidosis ii, mucopolysaccharidosis vi